Cargando…

Cancer Loyalty Card Study (CLOCS): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis

INTRODUCTION: Ovarian cancer is the eighth most common cancer in women worldwide, and about 1 in 5 women with ovarian cancer do not receive treatment, because they are too unwell by the time they are diagnosed. Symptoms of ovarian cancer are non-specific or can be associated with other common condit...

Descripción completa

Detalles Bibliográficos
Autores principales: Brewer, Hannah R, Hirst, Yasemin, Sundar, Sudha, Chadeau-Hyam, Marc, Flanagan, James M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484869/
https://www.ncbi.nlm.nih.gov/pubmed/32900761
http://dx.doi.org/10.1136/bmjopen-2020-037459
_version_ 1783581061202051072
author Brewer, Hannah R
Hirst, Yasemin
Sundar, Sudha
Chadeau-Hyam, Marc
Flanagan, James M
author_facet Brewer, Hannah R
Hirst, Yasemin
Sundar, Sudha
Chadeau-Hyam, Marc
Flanagan, James M
author_sort Brewer, Hannah R
collection PubMed
description INTRODUCTION: Ovarian cancer is the eighth most common cancer in women worldwide, and about 1 in 5 women with ovarian cancer do not receive treatment, because they are too unwell by the time they are diagnosed. Symptoms of ovarian cancer are non-specific or can be associated with other common conditions, and women experiencing these symptoms have been shown to self-manage them using over-the-counter medication. Results from a recent proof-of-concept study suggest there may be an increase in the purchases of painkillers and indigestion medication 10–12 months before ovarian cancer diagnosis. We propose a case–control study, as part of a larger project called the Cancer Loyalty Card Study (CLOCS), to investigate whether a significant change in medication purchases could be an indication for early signs of ovarian cancer, using data already collected through store loyalty cards. METHODS AND ANALYSIS: Using a retrospective case–control design, we aim to recruit 500 women diagnosed with ovarian cancer (cases) and 500 women without ovarian cancer (controls) in the UK who hold a loyalty card with at least one participating high street retailer. We will use pre-existing loyalty card data to compare past purchase patterns of cases with those of controls. In order to assess ovarian cancer risk in participants and their purchase patterns, we will collect information from participants on ovarian cancer risk factors and clinical data including symptoms experienced before diagnosis from recruited women with ovarian cancer. ETHICS AND DISSEMINATION: CLOCS was reviewed and approved by the North West-Greater Manchester South Research Ethics Committee (19/NW/0427). Study outcomes will be disseminated through academic publications, the study website, social media and a report to the research sites that support the study once results are published. TRIAL REGISTRATION NUMBER: ISRCTN 14897082, CPMS 43323, NCT03994653.
format Online
Article
Text
id pubmed-7484869
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74848692020-09-18 Cancer Loyalty Card Study (CLOCS): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis Brewer, Hannah R Hirst, Yasemin Sundar, Sudha Chadeau-Hyam, Marc Flanagan, James M BMJ Open Oncology INTRODUCTION: Ovarian cancer is the eighth most common cancer in women worldwide, and about 1 in 5 women with ovarian cancer do not receive treatment, because they are too unwell by the time they are diagnosed. Symptoms of ovarian cancer are non-specific or can be associated with other common conditions, and women experiencing these symptoms have been shown to self-manage them using over-the-counter medication. Results from a recent proof-of-concept study suggest there may be an increase in the purchases of painkillers and indigestion medication 10–12 months before ovarian cancer diagnosis. We propose a case–control study, as part of a larger project called the Cancer Loyalty Card Study (CLOCS), to investigate whether a significant change in medication purchases could be an indication for early signs of ovarian cancer, using data already collected through store loyalty cards. METHODS AND ANALYSIS: Using a retrospective case–control design, we aim to recruit 500 women diagnosed with ovarian cancer (cases) and 500 women without ovarian cancer (controls) in the UK who hold a loyalty card with at least one participating high street retailer. We will use pre-existing loyalty card data to compare past purchase patterns of cases with those of controls. In order to assess ovarian cancer risk in participants and their purchase patterns, we will collect information from participants on ovarian cancer risk factors and clinical data including symptoms experienced before diagnosis from recruited women with ovarian cancer. ETHICS AND DISSEMINATION: CLOCS was reviewed and approved by the North West-Greater Manchester South Research Ethics Committee (19/NW/0427). Study outcomes will be disseminated through academic publications, the study website, social media and a report to the research sites that support the study once results are published. TRIAL REGISTRATION NUMBER: ISRCTN 14897082, CPMS 43323, NCT03994653. BMJ Publishing Group 2020-09-08 /pmc/articles/PMC7484869/ /pubmed/32900761 http://dx.doi.org/10.1136/bmjopen-2020-037459 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Oncology
Brewer, Hannah R
Hirst, Yasemin
Sundar, Sudha
Chadeau-Hyam, Marc
Flanagan, James M
Cancer Loyalty Card Study (CLOCS): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis
title Cancer Loyalty Card Study (CLOCS): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis
title_full Cancer Loyalty Card Study (CLOCS): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis
title_fullStr Cancer Loyalty Card Study (CLOCS): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis
title_full_unstemmed Cancer Loyalty Card Study (CLOCS): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis
title_short Cancer Loyalty Card Study (CLOCS): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis
title_sort cancer loyalty card study (clocs): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484869/
https://www.ncbi.nlm.nih.gov/pubmed/32900761
http://dx.doi.org/10.1136/bmjopen-2020-037459
work_keys_str_mv AT brewerhannahr cancerloyaltycardstudyclocsprotocolforanobservationalcasecontrolstudyfocusingonthepatientintervalinovariancancerdiagnosis
AT hirstyasemin cancerloyaltycardstudyclocsprotocolforanobservationalcasecontrolstudyfocusingonthepatientintervalinovariancancerdiagnosis
AT sundarsudha cancerloyaltycardstudyclocsprotocolforanobservationalcasecontrolstudyfocusingonthepatientintervalinovariancancerdiagnosis
AT chadeauhyammarc cancerloyaltycardstudyclocsprotocolforanobservationalcasecontrolstudyfocusingonthepatientintervalinovariancancerdiagnosis
AT flanaganjamesm cancerloyaltycardstudyclocsprotocolforanobservationalcasecontrolstudyfocusingonthepatientintervalinovariancancerdiagnosis